: A Critical Competing Endogenous RNA in Cancer Research - A Scoping Review

Sadra Salehi-Mazandarani,Sharareh Mahmoudian-Hamedani,Ziba Farajzadegan,Parvaneh Nikpour
DOI: https://doi.org/10.1101/2024.04.22.24306181
2024-04-22
Abstract:In recent years, research on the competing endogenous RNAs (ceRNAs) in cancer is in full swing. These investigations are discovering the importance of critical RNAs in cancer progression. Enhancer of zeste 2 polycomb repressive complex 2 subunit ( ) is one of these RNAs that has been identified as a potential therapeutic target in many types of cancer. Up to now, many studies have been conducted to elucidate ceRNA role of in cancer. Due to EZH2’s dual role as an oncogene and tumor suppressor in cancer, a more thorough exploration of its ceRNA functions may enhance clinical approaches to cancer treatment. In the current scoping review, we searched online databases including PubMed, Web of Science, Scopus, Embase, Cochrane Library, and Google Scholar to identify experimentally-validated ceRNA axes including in human cancers. We identified 62 unique axes consisting of 30 microRNAs (miRNAs), 31 long non-coding RNAs (lncRNAs), 9 messenger RNAs (mRNAs), and 14 circular RNAs (circRNAs). Notably, - miR-101-3p - and - miR-101-3p - were recurrent axes observed in multiple cancer types. Among the most frequent miRNAs were miR-101-3p, miR-144-3p, and miR-124-3p, and ceRNAs including , , , , , and emerged as frequent competitors of for miRNA binding. This scoping review highlights the prevalence and diversity of -containing ceRNA axes in cancer, suggesting their potential as therapeutic targets. Future research should delve deeper into these axes to elucidate their functional significance and assess their clinical applicability.
Genetic and Genomic Medicine
What problem does this paper attempt to address?